Skip to content

Comparative effectiveness of pain management in adjunctive intercostal nerve block versus conventional analgesia alone in severe blunt chest trauma population : a prospective study

Comparative effectiveness of pain management in adjunctive intercostal nerve block versus conventional analgesia alone in severe blunt chest trauma population : a prospective study

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
TCTR
Registry ID
TCTR20250205002
Enrollment
42
Registered
2025-02-05
Start date
2025-04-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

add on intercostal nerve block to relieve pain in patients with blunt chest trauma blunt chest trauma , intercostal nerve block , multimodal analgesis

Interventions

multimodal analgesia consist of 1. paracetamol 2. NSAIDs 3. TCA : amitriptylene 4. Gabapentinoids : gabapentin 5. muslce relaxant : mydocalm,0.5% bupivacaine add on multimodal analgesia *we compare
Experimental Drug,Experimental Drug
multimodal analgesia,intercostal nerve block

Sponsors

None listed

Eligibility

Sex/Gender
All
Age
18 Years to 79 Years

Inclusion criteria

Inclusion criteria: 1. blunt traumatic chest trauma patients were registered in Maharaj Nakorn Ratchasima hospital 2.Age 18-79 years old with diagnosis of rib fracture with or without pneumohemothorax 3. Chest trauma score more than 6 point and pain score more than 7 point 4. injury occurs less than 48 hr.

Exclusion criteria

Exclusion criteria: 1. unstable vital signs with inotropic or vasopressor drug 2. proved intraabdominal injury 3. morbid obesity BMI > 35 4. Moderate to severe traumatic brain injury (GSC < 13) 5. Onset of injury > 72hr. 6. Major bone fracture e.g. pelvic fracture , femur fracture, both bone of leg 7. Intubated patients on arrival/ before admission 8. pregnancy or breast feeding 9. Immuno-compromised host HIV with opportunistic infection or CD4 count < 200 cells/cu.mm Autoimmune disease with steroid use 10. Heart or great vessel injury 11. Cervical or thoracic spine injury with loss of sensation 12. Anticoagulation or antiplatelet used

Design outcomes

Primary

MeasureTime frame
pain score 3 month verbal pain score and facial pain scale

Secondary

MeasureTime frame
pulmonary complication 3 month clinical and investigation,pneumonia 3 months clinical and investigation,ARDS 3 month clinical and investigation,require intubation 3 month clinical and investigation,lung ateletasis 3 month clinical and investigation,pulmonart embolism 3 month clinical and investigation,duration of chest tune drain 3 month clinical and investigation,lenght of ICU/hospital stay 3 month clinical and investigation,30 day mortality and complication from procedure e.g hemothorax,pneumothorax,he,hematoma 3 month clinical and investigation

Countries

Thailand

Contacts

Public ContactPISIT SABANGBAN

Maharat Nakorn ratchasima hospital

pisit_tle@hotmail.com0873735734

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026